Why Brinker International Shares Look Tasty  2020/10/16 23:30:00 Barron's
Margin improvements and cost cuts could produce earnings above $5 a share when the pandemic ends. Also, Wall Street opinions on the stocks of UnitedHealth Group, PNC Financial Services, Albertsons, and Mesoblast
   ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Mesoblast Limited Investors of Important December 7 Deadline in Securities Class Action– MESO  2020/10/16 21:01:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mesoblast Limited (NASDAQ: MESO) between April 16, 2019 and October 1, 2020, inclusive (the “Class Period”), of the important December 7, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Mesoblast investors under the federal securities laws. To join the Mesoblast class action, go to
   Stem Cell Market 2020 – Impact of COVID-19, Future Growth Analysis and Challenges | Anterogen Co., Ltd, Mesoblast Ltd, Osiris Therapeutics, Inc, AlloSource  2020/10/16 10:59:28 OpenPR
The Business Research Company offers "Stem Cell Global Market Report 2020-30: Covid 19 Growth And Change" in its research report store. It is the most comprehensive report available on this market and will help gain a truly global perspective as
   Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Mesoblast Limited (MESO)  2020/10/15 15:30:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $MESO #CLASSACTION--Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Mesoblast Limited (MESO)
   Notice of Lead Plaintiff Deadline for Shareholders in the Mesoblast Limited Class Action Lawsuit  2020/10/14 13:00:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning Mesoblast business and prospects, resulting in its stock trading at inflated prices.
   Great start to the week for Aussie stocks: ASX closed 2.6% higher  2020/10/05 06:21:39 Finance News Network
05 Oct 2020 - It has been a positive day of trade for the ASX the local bourse managed to close 2.6% higher. Shares in Mesoblast (ASX:MSB) did well today, rising over 11%. Gold miners were hit today though with Evolution Mining (ASX:EVN) and Newcrest (ASX:NCM) both falling. McMillan Shakespeare (ASX:MMS) has settled a class action today.
   The Week Ahead In Biotech: Avenue's FDA Decision, Alkermes Adcom Meeting, Aziyo Biologics IPO  2020/10/04 14:00:07 Benzinga
Biotech stocks made a steady recovery over the week ended Oct. 2, although Friday's weakness trimmed some of the gains of the week. Companies working on anti-COVID-19 antibody treatments were in the news during the week. Sorrento Therapeutics Inc. (NASDAQ: SRNE ) announced a second more potent preclinical antibody candidate, while Regeneron Pharmaceuticals Inc. (NASDAQ: REGN ) released preliminary readout for its antibody cocktail in treating non-hospitalized COVID-19 patients. On the FDA approval front, Eton Pharmaceuticals Inc. (NASDAQ: ETON ) received the nod for its Alkindi Sprinkle as a hormone replacement therapy for treating adrenocortical insufficiency in children under 17 years of age. Mesoblast (NASDAQ: MESO ), however, was in for a disappointment. Its stem cell therapy for acute graft versus host disease was turned down by the regulatory agency. Zosano Pharma Corp. (NASDAQ: ZSAN ) shares wilted on a deficiency review letter for the NDA for its migraine patch. Selecta Biosciences Inc.
   Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Mesoblast Limited (MESO) on Behalf of Investors  2020/10/03 00:28:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $MESO #CLASSACTION--Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Mesoblast Limited (MESO) on Behalf of Investors
   Mesoblast (ASX:MSB) hits approval hurdle: Aus shares 0.9% lower at noon  2020/10/02 04:16:41 Finance News Network
02 Oct 2020 - The Australian share market opened lower and continued to sink in early trade. Most of the sectors have lost ground this morning, with energy stocks weighing heaviest on the market. Shares in regenerative medicine darling Mesoblast (ASX:MSB) tumbled around 40% this morning after news that the US FDA approval for its lead drug candidate was not going to be the smooth sailing investors had hoped for.
   Heavyweights knock ASX lower; Tech soars; Mesoblast hammered  2020/10/02 02:16:53 TheAge
All the latest ASX news from Markets Live team. Reporting on the ASX200 today, Australia's top stocks, the Aussie dollar (AUD), and breaking business news
   Mesoblast's (ASX:MSB) good COVID-19 news | Rask Media  2020/09/04 22:15:04 Rask Media
Mesoblast Limited (ASX:MSB) shares dropped 3% on Friday after announcing news relating to COVID-19 patients.
   Buy, hold, sell: Telstra, CSL, Mesoblast, Dacian Gold, EML Payments  2020/09/04 01:56:52 The Australian Financial Review
These stocks are the most searched-for on Livewire Markets – but are they a buy?
   The Daily Biotech Pulse: Amarin's Vascepa Appeal Hearing, Avid Bioservices' Strong Q1, A Life Sciences Blank Check IPO  2020/09/02 11:25:11 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 1) 10X Genomics Inc (NASDAQ: TXG ) Acutus Medical Inc (NASDAQ: AFIB ) Akouos Inc (NASDAQ: AKUS ) Catalent Inc (NYSE: CTLT ) Evogene Ltd (NASDAQ: EVGN ) (announced $10 million equity investment led by ARK Investment Management) I-Mab ADR (NASDAQ: IMAB ) Immunomedics, Inc. (NASDAQ: IMMU ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Pacific Biosciences of California Inc (NASDAQ: PACB ) PPD Inc (NASDAQ: PPD ) Shockwave Medical Inc (NASDAQ: SWAV ) Tandem Diabetes Care Inc (NASDAQ: TNDM ) TG Therapeutics Inc common stock (NASDAQ: TGTX ) Twist Bioscience Corp (NASDAQ: TWST ) West Pharmaceutical Services Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 1) Acasti Pharma Inc (NASDAQ: ACST ) ADiTx Therapeutics Inc (NASDAQ: ADTX ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Entera Bio Ltd (NASDAQ: ENTX ) Freeline Therapeutics Holdings PLC (NASDAQ: FRLN ) Happiness Biotech Group Ltd (NASDAQ: HAPP ) Histogen Inc (NASDAQ: HSTO ) Immatics NV (NASDAQ: IMTX ) NanoVibronix Inc (NASDAQ: NAOV ) Oncternal Therapeutics Inc (NASDAQ: ONCT ) Predictive Oncology Inc (NASDAQ: POAI ) Rockwell Medical Inc (NASDAQ: RMTI ) Sun BioPharma, Inc. (NASDAQ: SNBP ) Stocks In Focus Mesoblast Gets Ethics Approval For Using Stem Cell Therapy In COVID-19 Patients In Australia Mesoblast (NASDAQ: MESO ) said it has received ethics approval to include Australian hospitals in the Phase 3 randomized controlled trial of remestemcel-L in ventilator-dependent COVID-19 patients with acute respiratory distress syndrome.
   Mesoblast (ASX:MSB) receives ethics approval to treat Covid-19 patients  2020/09/02 01:41:00 Finance News Network
02 Sep 2020 - Mesoblast (ASX:MSB) today announced that it has received ethics approval to include Australian hospitals in the controlled trial of remestemcel-L Covid-19 patients with acute respiratory distress syndrome (ARDS).
   Mesoblast reports FY results (NASDAQ:MESO)  2020/08/27 06:06:05 Seeking Alpha
Mesoblast (NASDAQ:MESO): FY GAAP EPS of -$0.147. Revenue of $32.16M (+92.3% Y/Y) The company reported 32% increase in royalty revenue on Temcell HS. Inj. s